Cell and Gene Therapies

Aug 09, 2018
By BioPharm International Editors
The combined companies will provide research- and clinical-grade human immune cells, blood products, and related services.
Aug 08, 2018
By BioPharm International Editors
Avalon and Weill will co-develop bio-production and standardization procedures for CAR-T therapy.
Aug 06, 2018
By BioPharm International Editors
Boehringer Ingelheim joins Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, and Imperial Innovations to form a partnership for developing a new gene therapy to treat cystic fibrosis.
Aug 06, 2018
By BioPharm International Editors
The companies will collaborate on the discovery, development, and commercialization of cell therapies for cancer.
Aug 01, 2018
BioPharm International
The changing regulatory and manufacturing environment is ushering in a new approach to drug development.
Aug 01, 2018
By BioPharm International Editors
The companies will work together to develop novel gamma delta T-cell receptor therapies in various cancers.
Jul 26, 2018
By BioPharm International Editors
The acquisition would combine Sangamo’s ex vivo gene-editing capabilities with TxCell's regulatory T-cell (Treg) expertise to create chimeric antigen receptor (CAR)-Treg therapies.
Jul 19, 2018
By BioPharm International Editors
The company has run into a snag in producing Kymriah for the diffuse large B-cell lymphoma patient population, the second indication for which the therapy was recently approved by FDA.
Jul 18, 2018
By BioPharm International Editors
CELLforCURE will produce cancer CAR-T treatments for Novartis at a manufacturing facility in Les Ulis (Essonne), France.
Jul 12, 2018
By BioPharm International Editors
The agency is releasing six new draft guidances to provide a regulatory framework for handling gene therapies.
native1_300x100
lorem ipsum